How to buy Cue Biopharma stock | $13.04

Cue Biopharma, Inc is a biotechnology business based in the US. Cue Biopharma shares (CUE) are listed on the NASDAQ and all prices are listed in US Dollars. Cue Biopharma employs 45 staff and has a trailing 12-month revenue of around USD$3.7 million.

How to buy shares in Cue Biopharma

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Cue Biopharma. Find the stock by name or ticker symbol: CUE. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cue Biopharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$13.04, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cue Biopharma, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Cue Biopharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cue Biopharma share price

Use our graph to track the performance of CUE stocks over time.

Cue Biopharma shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$13.04
52-week range	USD$9.3 - USD$31.69
50-day moving average	USD$12.829
200-day moving average	USD$17.3859
Wall St. target price	USD$31.17
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.197

Buy Cue Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Cue Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cue Biopharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cue Biopharma price performance over time

Historical closes compared with the close of $13.04 from 2020-12-09

1 week (2021-01-07)	0.54%
1 month (2020-12-17)	1.09%
3 months (2020-10-15)	-14.99%
6 months (2020-07-15)	-40.83%

1 year (2020-01-15)	-17.88%
2 years (2019-01-15)	138.83%
3 years (2018-01-13)	N/A
5 years (2016-01-13)	N/A

Cue Biopharma financials

Revenue TTM	USD$3.7 million
Gross profit TTM	USD$-24,029,154
Return on assets TTM	-35.47%
Return on equity TTM	-74.36%
Profit margin	0%
Book value	$2.894
Market capitalisation	USD$397.3 million

TTM: trailing 12 months

Shorting Cue Biopharma shares

There are currently 2.9 million Cue Biopharma shares held short by investors – that's known as Cue Biopharma's "short interest". This figure is 0.8% down from 2.9 million last month.

There are a few different ways that this level of interest in shorting Cue Biopharma shares can be evaluated.

Cue Biopharma's "short interest ratio" (SIR)

Cue Biopharma's "short interest ratio" (SIR) is the quantity of Cue Biopharma shares currently shorted divided by the average quantity of Cue Biopharma shares traded daily (recently around 270917.53554502). Cue Biopharma's SIR currently stands at 10.55. In other words for every 100,000 Cue Biopharma shares traded daily on the market, roughly 10550 shares are currently held short.

However Cue Biopharma's short interest can also be evaluated against the total number of Cue Biopharma shares, or, against the total number of tradable Cue Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cue Biopharma's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Cue Biopharma shares in existence, roughly 90 shares are currently held short) or 0.0909% of the tradable shares (for every 100,000 tradable Cue Biopharma shares, roughly 91 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cue Biopharma.

Find out more about how you can short Cue Biopharma stock.

Cue Biopharma share dividends

We're not expecting Cue Biopharma to pay a dividend over the next 12 months.

Cue Biopharma share price volatility

Over the last 12 months, Cue Biopharma's shares have ranged in value from as little as $9.3 up to $31.69. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cue Biopharma's is 1.9874. This would suggest that Cue Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cue Biopharma overview

Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, an onco-fetal viral antigen for cancers, including solid tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases, as well as a strategic research collaboration with Dr. Michael Dustin and Oxford University. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Cue Biopharma is owned by insiders or institutions?

  Currently 10.756% of Cue Biopharma shares are held by insiders and 65.207% by institutions.

• How many people work for Cue Biopharma?

  Latest data suggests 45 work at Cue Biopharma.

• When does the fiscal year end for Cue Biopharma?

  Cue Biopharma's fiscal year ends in December.

• Where is Cue Biopharma based?

  Cue Biopharma's address is: 21 Erie Street, Cambridge, MA, United States, 02139

• What is Cue Biopharma's ISIN number?

  Cue Biopharma's international securities identification number is: US22978P1066

• What is Cue Biopharma's CUSIP number?

  Cue Biopharma's Committee on Uniform Securities Identification Procedures number is: 22978P106